Agios Pharmaceuticals (AGIO -5.96%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with GAAP net product revenue of $12.5 million, yet also highlighted the company's increasing cost base as it prepares for major regulatory events and launches. Overall, the quarter delivered strong revenue momentum, but at t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of Inc ...

Agios Pharmaceuticals (AGIO) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Company ParticipantsMorgan Sanford - VP - IRBrian Goff - CEO & DirectorCecilia Jones - CFOTsveta Milanova - Chief Commercial OfficerSarah Gheuens - Chief Medical Officer and Head of Research & DevelopmentImogen Mansfield - VP - Biotech Equity ResearchSalveen Richter - Biotechnology Equity ResearchAndrew Berens - Senior MD - Targeted OncologyTheresa Robb - Director & Head, Global Client Experience Centre Regulatory Governance & Inte ...

Agios Pharmaceuticals (AGIO) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Good morning and welcome to Agio's Second Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at Agio's request. I would now like to turn the call over to Agio.Please go ahead.Speaker1Thank you, operator. Good morning, everyone. I'm Morgan Sanford, Vice President of Inv ...

Financial Performance - PYRUKYND net revenues reached $12.5 million in Q2 2025, a 44% increase compared to $8.7 million in Q1 2025 and a 45% increase compared to $8.6 million in Q2 2024[10] - The company maintains a strong financial position with $1.3 billion in cash on hand[9, 10, 14] - Net loss for Q2 2025 was $112.0 million, compared to a net loss of $96.1 million for Q2 2024[14] Pipeline Development - First patient dosed in Phase 2 Sickle Cell Disease trial for AG-236 after receiving IND clearance[11] - RISE UP Phase 3 trial in sickle cell disease is expected to have topline data by the end of 2025[37] - Tebapivat Phase 2b trial for LR-MDS is ongoing, with topline results expected in early 2026[9, 45] Commercialization - 248 unique PK deficiency patients completed prescription enrollment forms since launch in the U S [21] - 142 patients are on treatment in the U S , including new prescriptions and treatment continuations, with 215 unique prescribers[22] - The company anticipates a potential U S launch of PYRUKYND for thalassemia in Q3 2025, with a PDUFA goal date of September 7, 2025[11, 23, 24] Strategic Partnerships - Announced a commercialization and distribution partnership with Avanzanite Bioscience in Europe[10] - A commercialization and distribution agreement is in place with NewBridge for the GCC region, with anticipated first regulatory approval in the coming months[30]

Exhibit 99.1 Agios Reports Second Quarter 2025 Financial Results and Provides Business Update CAMBRIDGE, Mass., July 31, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial- stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2025. • $12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, ca ...

$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG- ...

Core Insights - Agios Pharmaceuticals has appointed Dr. Jay Backstrom to its Board of Directors, which is expected to enhance the company's strategic direction and clinical program advancements [1][2][3] Company Overview - Agios Pharmaceuticals is a leader in cellular metabolism and pyruvate kinase (PK) activation, focusing on therapies for rare diseases [1][4] - The company markets a first-in-class PK activator for adults with PK deficiency, representing the first disease-modifying therapy for this condition [4] Leadership and Expertise - Dr. Backstrom brings extensive experience from his previous roles, including President and CEO of Scholar Rock and Executive Vice President of Research and Development at Acceleron Pharma [2][3] - His leadership has been instrumental in advancing clinical programs to regulatory approval, particularly in rare diseases [2][3] Strategic Focus - Agios is focused on maximizing the potential of its PK activator, PYRUKYND (mitapivat), and advancing its pipeline of rare disease medicines [2][3] - The company is developing investigational medicines for conditions such as alpha- and beta-thalassemia, sickle cell disease, and myelodysplastic syndromes [4]

The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. Investor Contact Morgan Sanford, Vice President, Investor Relations Agios Pharmaceuticals IR@agios.com Media Contact Eamonn Nolan, Senior Director, Corporate Communications Agios Pharmaceuticals Media@agios.com About Agios Agios is the pioneering leader ...

Agios Pharmaceuticals (AGIO) 2025 Conference May 21, 2025 08:00 AM ET Speaker0 Great. Good morning, everyone. We're going to get started, and welcome back to day two of the twenty twenty five RBC Global Healthcare Conference. My name is Greg Renzo, of the biotech analysts, and we're pleased to be joined today by Agios Pharmaceuticals. And and joining us from from the company is the chief executive officer, Brian Goff, as well as the chief financial officer, Cecilia Jones. Guys, it's great to great to have y ...